Department of Pharmacology, Bharati Vidyapeeth University, Erandwane, Pune, Maharashtra, India.
Eur J Pharmacol. 2010 Apr 25;632(1-3):103-9. doi: 10.1016/j.ejphar.2010.01.019. Epub 2010 Feb 1.
The aim of the present investigation was to evaluate the antidiabetic activity of cycloart-23-ene-3beta, 25-diol (called as B2) isolated from stem bark of Pongamia pinnata in streptozotocin-nicotinamide induced diabetic mice. Diabetes was induced in mice by injecting streptozotocin (200mg/kg, i.p.) after 15 min nicotinamide (110 mg/kg, i.p.). The mice were divided into following groups; I - nondiabeteic, II - diabetic control, III - glybenclamide (10mg/kg, p.o.), IV - B2 (1mg/kg, p.o.) and V - B2 (3mg/kg, p.o., only for acute study). Serum glucose was determined periodically. Body weight, food and water intake were recorded daily. Oral glucose tolerance test was performed on day 28. Biochemical and enzyme antioxidant parameters were determined. Histology of pancreas was performed. B2 and glybenclamide treatment reduced serum glucose in acute study. However in chronic study, increase in body weight and decrease in food and water intake was observed. Increased glucose utilization was observed in oral glucose tolerance test. Both glybenclamide and B2 increased serum and pancreatic insulin. Glycosylated haemoglobin, serum cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, globulin, bilirubin, lactate dehydrogenase, urea and uric acid were decreased significantly after B2 treatment. B2 treatment decreased liver malondialdehyde but increased superoxidase dismutase and reduced glutathione. Histologically, focal necrosis was observed in the diabetic mouse pancreata but was less obvious in treated groups. The mechanism of B2 appears to be due to increased pancreatic insulin secretion and antioxidant activity.
本研究旨在评估从麻疯树茎皮中分离得到的环阿尔廷-23-烯-3β，25-二醇（称为 B2）在链脲佐菌素-烟酰胺诱导的糖尿病小鼠中的抗糖尿病活性。通过在 15 分钟后注射链脲佐菌素（200mg/kg，ip）诱导小鼠糖尿病烟酰胺（110mg/kg，ip）。将小鼠分为以下几组：I-非糖尿病，II-糖尿病对照，III-格列本脲（10mg/kg，po），IV-B2（1mg/kg，po）和 V-B2（3mg/kg，仅用于急性研究，po）。定期测定血清葡萄糖。每日记录体重、食物和水的摄入量。第 28 天进行口服葡萄糖耐量试验。测定生化和酶抗氧化参数。进行胰腺组织学检查。B2 和格列本脲治疗在急性研究中降低了血清葡萄糖。然而，在慢性研究中，观察到体重增加和食物和水摄入量减少。口服葡萄糖耐量试验显示葡萄糖利用率增加。格列本脲和 B2 均增加了血清和胰腺胰岛素。糖化血红蛋白、血清胆固醇、甘油三酯、天冬氨酸氨基转移酶、丙氨酸氨基转移酶、碱性磷酸酶、球蛋白、胆红素、乳酸脱氢酶、尿素和尿酸在 B2 治疗后显著降低。B2 处理降低了肝脏丙二醛，但增加了超氧化物歧化酶和还原型谷胱甘肽。组织学上，糖尿病小鼠胰腺中观察到局灶性坏死，但在治疗组中不太明显。B2 的作用机制似乎是由于胰腺胰岛素分泌增加和抗氧化活性增强。
